Focused on precision oncology and rare genetic diseases, this biotech reported a significant insider sale amid strong ...

Tyra Biosciences was added to the S&P Biotechnology Select Industry Index on December 13, 2025, marking its inclusion alongside a broader group of U.S.-listed biotech peers. This milestone, alongside ...

CARLSBAD, Calif., May 25, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large ...

A live webcast of the Jefferies event can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event. Tyra Biosciences, Inc. ...

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Tyra Biosciences (TYRA) to $30 from $32 and keeps a Buy rating on the shares. The firm says TYRA-300 data in ...

Fintel reports that on December 16, 2025, Wedbush maintained coverage of Tyra Biosciences (NasdaqGS:TYRA) with a Outperform recommendation. Analyst Price Forecast Suggests 45.25% Upside As of December ...

TYRA-300 is the Company's lead precision medicine program stemming from its in-house SNÅP platform. TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the ...

On Thursday, Tyra Biosciences, Inc. (NASDAQ:TYRA) released clinical proof-of-concept data for TYRA-300 in patients with metastatic urothelial (mUC) cancer from its ongoing SURF301 Phase 1/2 study.

Tyra Bioscience ( (TYRA)) has provided an announcement. Tyra Biosciences announced promising interim clinical results for TYRA-300 in metastatic urothelial cancer, with significant anti-tumor activity ...